Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 8:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 3,777 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: ARMS Clear all
Terminated Phase 2 Interventional Results available

A Study to Assess the Safety and Effectiveness of Pridopidine Compared to Placebo in the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease

NCT03922711
View directory record Official record
Conditions
Parkinson Disease
Interventions
Pridopidine, Placebo
Drug
Lead sponsor
Prilenia
Industry
Eligibility
30 Years to 85 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
33
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2022 · Synced Oct 21, 2026, 8:05 AM EDT
Completed Phase 3 Interventional Results available

A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type

NCT03548584
View directory record Official record
Conditions
Agitation Associated With Alzheimer's Dementia, Alzheimer Dementia
Interventions
Brexpiprazole, Placebo
Drug · Other
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
55 Years to 90 Years
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 21, 2026, 8:05 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM

NCT02058147
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Insulin glargine/lixisenatide Fixed Ratio Combination, Insulin glargine (HOE901), Lixisenatide (AVE0010), Metformin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
1,170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
118
States / cities
Phoenix, Arizona • Tempe, Arizona • Little Rock, Arkansas + 98 more
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 21, 2026, 8:05 AM EDT
Terminated Phase 2 Interventional Results available

Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer

NCT04853043
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Cetuximab
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 21, 2026, 8:05 AM EDT
Completed Phase 2 Interventional Results available

A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib

NCT03239340
View directory record Official record
Conditions
EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Interventions
Osimertinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
Athens, Georgia • Atlanta, Georgia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Oct 21, 2026, 8:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

An App-based Mindfulness Intervention for Sexual Minority Women With a History of Early Life Adversities (ELA)

NCT05201391
View directory record Official record
Conditions
Overweight and Obesity
Interventions
"Eat Right Now" (ERN) mobile application
Behavioral
Lead sponsor
Brown University
Other
Eligibility
30 Years to 55 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 8, 2022 · Synced Oct 21, 2026, 8:05 AM EDT
Completed Phase 2 Interventional Results available

LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations

NCT00525148
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
BIBW 2992
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 99 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
23
States / cities
Bakersfield, California • Beverly Hills, California • Mission Hills, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2016 · Synced Oct 21, 2026, 8:05 AM EDT
Completed Not applicable Interventional

Impact of Enhanced Daily Disinfection on Environmental Contamination in Hospital Rooms

NCT05739955
View directory record Official record
Conditions
Disinfection
Interventions
Sani24, Standard EPA-registered disinfectant, Routine Disinfection
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 21, 2026, 8:05 AM EDT
Recruiting Not applicable Interventional

Personalized Health Self-Management Training for Colorectal Cancer Survivors

NCT05984589
View directory record Official record
Conditions
Colorectal Cancer, Healthy Lifestyle, Behavior, Health, Health Behavior, Gastrointestinal Cancers
Interventions
RISE Personalized Self-Management Training (PSMT), Standardized Self-Management Training (SSMT)
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 21, 2026, 8:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Fast Bar on Physiological Fasting

NCT04499599
View directory record Official record
Conditions
Fasting
Interventions
Dinner, Fasting, Study food
Other
Lead sponsor
L-Nutra Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 9, 2024 · Synced Oct 21, 2026, 8:05 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia A

NCT04323098
View directory record Official record
Conditions
Hemophilia A
Interventions
valoctocogene roxaparvovec
Biological
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
18 Years and older · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Sacramento, California • St Louis, Missouri • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Oct 21, 2026, 8:05 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer

NCT02489448
View directory record Official record
Conditions
Breast Neoplasms
Interventions
MEDI4736
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Oct 21, 2026, 8:05 AM EDT
Completed Not applicable Interventional Results available

Study to Compare Efficacy of the MiniMed Paradigm REAL-Time System Vs. MDI in Subjects Naive to Insulin Pump Therapy

NCT00417989
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
MiniMed Paradigm REAL-Time System
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
7 Years to 70 Years
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
26
States / cities
La Jolla, California • Orange, California • Boulder, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Oct 21, 2026, 8:05 AM EDT
Terminated Phase 3 Interventional Results available

Study to Assess the Efficacy and Safety of NTRA-2112 on Intestinal Malabsorption in Preterm Infants

NCT02510560
View directory record Official record
Conditions
Premature Birth of Newborn, Intestinal Malabsorption
Interventions
NTRA-2112, Placebo
Drug
Lead sponsor
Elgan Pharma Ltd.
Industry
Eligibility
1 Day to 5 Days
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
4
States / cities
Greenville, North Carolina • Oklahoma City, Oklahoma • Charleston, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 21, 2026, 8:05 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age

NCT06641180
View directory record Official record
Conditions
Influenza
Interventions
High-Dose trivalent influenza vaccine (Split virion, Inactivated), Standard-dose trivalent influenza vaccine (Split virion, Inactivated)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
50 Years to 64 Years
Enrollment
1,180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
20
States / cities
Los Alamitos, California • Fort Myers, Florida • Hollywood, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 21, 2026, 8:05 AM EDT
Completed Phase 3 Interventional

FACTS I: A Study to Test the Safety and Effectiveness of a New Medication on the Treatment of Active Ulcerative Colitis

NCT00064441
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
OPC-6535 Tablets (drug)
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
23
States / cities
Scottsdale, Arizona • Los Angeles, California • Santa Ana, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 10, 2012 · Synced Oct 21, 2026, 8:05 AM EDT
Terminated No phase listed Observational

A Study of the ECHELON Contour Curved Cutter Stapler Device in Colorectal Procedures

NCT05133141
View directory record Official record
Conditions
Colorectal Surgical Procedures
Interventions
Echelon Contour
Device
Lead sponsor
Ethicon Endo-Surgery
Industry
Eligibility
Not listed
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
St Louis, Missouri • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Oct 21, 2026, 8:05 AM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)

NCT03085810
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Ocrelizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
26
States / cities
Irvine, California • Sunnyvale, California • Aurora, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 21, 2026, 8:05 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of RZ402 in Diabetic Macular Edema (DME)

NCT05712720
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Experimental: Group 1 - 50mg RZ402, Experimental: Group 2 - 200mg RZ402, Experimental: Group 3 - 400mg RZ402, Placebo: Group 4 - Placebo
Drug · Other
Lead sponsor
Rezolute
Other
Eligibility
18 Years to 75 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
32
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 21, 2026, 8:05 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Study of Healthy Aging and Physical Function With Elamipretide

NCT07275424
View directory record Official record
Conditions
Aging, Healthy
Interventions
Elamipretide will be supplied as a sterile 5.0 mL single-patient, multi-dose glass vial containing 3.75 mL of elamipretide solution (elamipretide [80 mg/mL], phosphate buffer, and benzyl alcohol)
Drug
Lead sponsor
David Marcinek
Other
Eligibility
65 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 21, 2026, 8:05 AM EDT
Completed Phase 1 Interventional

A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients

NCT01468688
View directory record Official record
Conditions
3rd Line GIST
Interventions
STI571, BKM120
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 21, 2026, 8:05 AM EDT
Completed Phase 3 Interventional Results available

Ultrasound Guided Supraclavicular Nerve Block

NCT00825786
View directory record Official record
Conditions
Local Anesthetic
Interventions
Ropivacaine, Mepivacaine
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 21, 2026, 8:05 AM EDT
Completed Not applicable Interventional Results available

RehabTouch Home Therapy for Stroke Patients

NCT03503617
View directory record Official record
Conditions
Cerebral Stroke
Interventions
RehabTouch, Conventional tabletop exercise program
Device · Other
Lead sponsor
Flint Rehabilitation Devices, LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Downey, California
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Oct 21, 2026, 8:05 AM EDT
Completed Phase 2 Interventional

A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults with Long COVID.

NCT05668091
View directory record Official record
Conditions
Long COVID
Interventions
Nirmatrelvir, Ritonavir, Placebo
Drug
Lead sponsor
Harlan M Krumholz
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Oct 21, 2026, 8:05 AM EDT